Royal Philips (NYSE: PHG, AEX: PHIA), a prominent player in health technology, has announced that the PreciseOnco consortium, led by Philips, has secured funding from the EU’s Innovative Health Initiative (IHI). This funding aims to enhance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies.
Key Details of the Initiative
- Funding Amount: €14.9 million from the EU, supplemented by €9 million in contributions from industry partners.
- Project Duration: Five-year research and innovation program.
- Total Budget: €23.9 million, which includes five clinical studies to validate technical solutions.
Goals of the PreciseOnco Consortium
The consortium aims to:
- Combine advanced medical imaging, robotic guidance technologies, and AI to standardize and improve the precision of minimally invasive cancer treatments.
- Set a new benchmark for precision, safety, and efficiency in cancer care.
Clinical Studies Overview
The project will include five clinical studies focusing on various cancer types and interventional workflows:
- VISTA: Evaluating spectral imaging for liver and kidney ablation procedures.
- SPOT ON: Assessing spectral CT for improved tumor targeting.
- HORA EST HCC 2: Combining thermal ablation with transarterial chemoembolization (TACE).
- SPECTRA-L: Testing spectral imaging for TACE procedures.
- LASER: Developing imaging biomarkers to predict treatment success across multiple cancer types.
Importance of the Initiative
Cancer remains a significant health challenge, with approximately 2.7 million new diagnoses in Europe annually. The PreciseOnco initiative addresses the growing need for effective cancer treatments by integrating:
- Spectral Imaging: Provides detailed information about tissue composition.
- Robotic Guidance: Ensures precise instrument navigation during procedures.
- AI Algorithms: Enhance image quality and provide real-time feedback during treatments.
This collaboration between industry, research organizations, and medical societies aims to improve cancer care delivery and patient outcomes across Europe.
For more information, visit the PreciseOnco project website.